Physician profile
Taylor Maher
NPI 1558020412
$7,519.30
in general payments reported to CMS, 2019-2025
35 companies · $2,764 in 2025
The $2,764 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,142 · 2023: $1,798 · 2024: $1,815 · 2025: $2,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,320 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,319.70 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,388.29 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $939.91 | 2022-2025 | Dupixent |
| Genzyme Corporation | $741.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $707.81 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Electromed, INC. | $603.88 | 2022-2025 | Smartvest |
| Harmony Biosciences LLC | $539.10 | 2022-2025 | Wakix |
| Actelion Pharmaceuticals US, INC. | $352.68 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $222.66 | 2024-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.39 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $210.03 | 2022-2024 | Yupelri |
| Verona Pharma, INC. | $174.02 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $132.23 | 2022-2024 | |
| Pfizer INC. | $124.34 | 2022-2024 | |
| Axsome Therapeutics, INC. | $118.73 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $116.46 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $100.69 | 2023-2024 | |
| Amgen INC. | $83.99 | 2022-2023 | Tezspire |
| Ani Pharmaceuticals, INC. | $77.52 | 2024-2025 | Purified Cortrophin Gel |
| Inogen, INC. | $71.13 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Grifols USA, LLC | $63.24 | 2025 | Prolastin-C Liquid |
| Philips North America LLC | $62.69 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Bayer Healthcare Pharmaceuticals INC. | $59.61 | 2022 | |
| Vifor Pharma, INC. | $59.50 | 2025 | Zemaira |
| Merck Sharp & Dohme LLC | $54.03 | 2023 | Belsomra |
| Pulmonx Corporation | $48.00 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| United Therapeutics Corporation | $37.45 | 2022 | |
| Baxter Healthcare | $34.08 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.79 | 2023 | Quviviq |
| Tactile Systems Technology INC | $29.53 | 2025 | Nimbl, Flexitouch Plus |
| Lilly USA, LLC | $28.41 | 2025 | Zepbound |
| Csl Behring | $22.29 | 2022 | |
| La Jolla Pharmaceutical Company | $18.42 | 2025 | Giapreza |
| Avadel Cns Pharmaceuticals, LLC | $17.15 | 2023 | Lumryz |
| Mallinckrodt Hospital Products INC. | $14.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.